[1] W, Y., et al., Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial. The Lancet. Oncology, 2021.

[2] XY, L., et al., Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol. BMC cancer, 2021. 21(1): p. 59.

[3] Kearney, S.L., et al., Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer, 2009. 53(2): p. 162-7.

[4] Gottschalk, H.S., et al., Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia. Blood, 2021. 137(17): p. 2373-2382.

[5] JG, K., Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. II. Studies on the nature of the active serum constituent: histological mechanism of the regression: tests for effects of guinea pig serum on lymphoma cells in vitro: discussion. The Journal of experimental medicine, 1953. 98(6): p. 583-606.

[6] JD, B., Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance. The Journal of experimental medicine, 1963. 118: p. 99-120.

[7] LT, M. and W. JC, TUMOR INHIBITORY EFFECT OF L-ASPARAGINASE FROM ESCHERICHIA COLI. Archives of biochemistry and biophysics, 1964. 105: p. 450-2.

[8] WK, C., et al., Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia. Molecular cancer therapeutics, 2019. 18(9): p. 1587-1592.

[9] Y, L., et al., Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. 37(23): p. 2051-2061.

[10] W, S., S. N and S. M, Erwinia asparaginase  in pediatric acute lymphoblastic leukemia. Expert opinion on biological therapy, 2012. 12(10): p. 1407-14.

[11] T, M. and G. D, Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase. Investigational new drugs, 2021.

[12] Vrooman, L.M., et al., Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer, 2010. 54(2): p. 199-205.

[13] Tong, W.H., et al., A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood, 2014. 123(13): p. 2026-33.

[14] LJ, B., et al., Hypersensitivity to Pegylated E.colia sparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group. European journal of cancer (Oxford, England : 1990), 2021. 162: p. 65-75.

[15] Y, L., et al., Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. Clinical pharmacology and therapeutics, 2021.

[16] Liu, S., et al., HLA-DRB1*16:02 is associated with PEG-asparaginase hypersensitivity. Pharmacogenomics, 2021.

[17] SL, C., et al., Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions. Pediatric blood & cancer, 2019. 66(8): p. e27797.

[18] A, S., H. P and P. L, Posterior Reversible Encephalopathy Syndrome in the Setting of Asparaginase-associated Pancreatitis in 2 Pediatric Patients With Acute Leukemia. Journal of pediatric hematology/oncology, 2021.

[19] Peng, S., et al., Calcium and adenosine triphosphate control of cellular pathology: asparaginase-induced pancreatitis elicited via protease-activated receptor 2. Philos Trans R Soc Lond B Biol Sci, 2016. 371(1700).

[20] Bartram, T., et al., Genetic Variation in ABCC4 and CFTR and Acute Pancreatitis during Treatment of Pediatric Acute Lymphoblastic Leukemia. J Clin Med, 2021. 10(21).

[21] Gibson, A., et al., Asparaginase-Associated Pancreatitis in Pediatric Patients with Acute Lymphoblastic Leukemia: Current Perspectives. Paediatr Drugs, 2021. 23(5): p. 457-463.

[22] Peng, S., et al., Calcium and adenosine triphosphate control of cellular pathology: asparaginase-induced pancreatitis elicited via protease-activated receptor 2. Philos Trans R Soc Lond B Biol Sci, 2016. 371(1700).

[23] Rank, C.U., et al., Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age. J Clin Oncol, 2020. 38(2): p. 145-154.

[24] 高琴丽等, 儿童急性淋巴细胞白血病化疗合并培门冬酶相关胰腺炎临床分析. 中国小儿血液与肿瘤杂志, 2021. 26(05): 第285-288+293页.

[25] V, C., et al., Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood, 2006. 108(7): p. 2216-22.

[26] K, S., et al., SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia. Clinical lymphoma, myeloma & leukemia, 2021.

[27] Athale, U.H., et al., Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Dana-Farber Cancer Institute ALL Consortium trial 05-001. Pediatr Blood Cancer, 2022: p. e29581.

[28] KB, J., et al., Candidate single nucleotide polymorphisms and thromboembolism in acute lymphoblastic leukemia - A NOPHO ALL2008 study. Thrombosis research, 2019. 184: p. 92-98.

[29] H, S., A. EG and S. JT, Prophylaxis with low-molecular- weight heparin reduces thrombotic events and allows continuation of asparaginase containing regimens during intensification phase. British journal of haematology, 2022.

[30] H, A., et al., Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. The pharmacogenomics journal, 2017. 17(3): p. 274-279.

[31] S, A., et al., Pharmacogenetics of induction therapy-related toxicities in childhood acute lymphoblastic leukemia patients treated with UKALL 2003 protocol. Scientific reports, 2021. 11(1): p. 23757.

[32] L, Y., et al., Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008. 26(12): p. 1932-9.

[33] S, A., et al., L-carnitine and Vitamin B Complex for PEG-L-asparaginase-Induced Hepatotoxicity. ACG case reports journal, 2019. 6(8): p. e00194.

[34] C, M., et al., Lipid Apheresis to Manage Severe Hypertriglyceridemia during Induction Therapy in a Child with Acute Lymphoblastic Leukemia. Pediatric hematology and oncology, 2020. 37(6): p. 530-538.

[35] J, Z., et al., Severe drug-induced hypertriglyceridemia treated with plasmapheresis in children with acute lymphoblastic leukemia. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2019. 58(5): p. 634-637.

[36] JV, L. and K. JD, Acute encephalopathy and hyperammonaemia complicating treatment of acute lymphoblastic leukaemia with asparaginase. Lancet (London, England), 1986. 1(8473): p. 162-3.

[37] N, G., et al., Symptomatic Hyperammonemia With Erwinia chrysanthemi-derived Asparaginase in Pediatric Leukemia Patients. Journal of pediatric hematology/oncology, 2018. 40(4): p. 312-315.

[38] MP, S., et al., L-Asparaginase Toxicity in the Treatment of Children and Adolescents with Acute Lymphoblastic Leukemia. Journal of clinical medicine, 2021. 10(19).

[39] LS, L., et al., Asparaginase Enzyme Activity Levels and Toxicity in Childhood Acute Lymphoblastic Leukemia: a NOPHO ALL2008 study. Blood advances, 2021.

[40] ER, F., et al., Fenofibrate reduces osteonecrosis without affecting antileukemic efficacy in dexamethasone treated mice. Haematologica, 2020.

[41] YK, V., et al., Orthopedic Toxicities Among Adolescents and Young Adults Treated on DFCI ALL Consortium Trials. Blood advances, 2021.